Epitalon (AEDG) Guide: Telomerase, Research Evidence and Regulatory Status

Epitalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG), a molecular weight of 390.35 Da, and a CAS number of 307297-39-8. It was developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a simplified synthetic analogue of epithalamin, a polypeptide fraction originally isolated from bovine pineal gland tissue in the 1970s.

The distinction between epithalamin and epitalon matters. Epithalamin is a crude pineal extract containing multiple peptides and other molecules. Khavinson’s group identified the four-amino-acid sequence AEDG as the putative active component and synthesised it as a standalone compound, initially calling it epitalon (sometimes written epithalon or epithalone in the Russian literature). The bulk of the published research, spanning more than three decades, has been produced by Khavinson’s institute and close collaborators, though independent telomerase work has started to appear in Western and Middle Eastern laboratories since the 2020s.

Epitalon is not approved by any national drug regulator for any therapeutic indication. It circulates in the longevity and biohacking communities primarily through research-use-only peptide suppliers, compounding pharmacies (in jurisdictions where compounding was historically permitted), and grey-market sources. In the United States, it was placed on the FDA’s Category 2 restricted list between 2023 and 2024, effectively blocking legal compounding. That Category 2 listing was removed on April 15, 2026, as part of the broader Kennedy-era peptide reclassification, and epitalon is now scheduled for PCAC review on July 24, 2026.

The bottom line: Epitalon is a four-amino-acid peptide with a 30-year preclinical research history centred on telomerase activation and melatonin restoration, now approaching its first formal US regulatory evaluation.

Epitalon’s proposed mechanisms fall into three overlapping pathways, though it is important to note that the mechanistic picture remains incomplete and draws predominantly from in vitro and animal data.

Telomerase Activation

The most cited mechanism is the activation of telomerase, the enzyme responsible for adding TTAGGG repeats to chromosome ends. Khavinson, Bondarev, and Butyugov (2003) demonstrated in the Bulletin of Experimental Biology and Medicine that adding epitalon to cultures of telomerase-negative human fetal lung fibroblasts induced expression of the catalytic subunit (hTERT), restored enzymatic telomerase activity as measured by the TRAP protocol, and produced measurable telomere elongation. A 2019 study by Pendina, Efimova, and colleagues from the same institute (Bulletin of Experimental Biology and Medicine) showed that epitalon increased telomere length and mitotic index in PHA-stimulated human blood lymphocytes. More recently, a 2025 study by Ullah and colleagues demonstrated that epitalon-activated telomerase enhanced bovine oocyte maturation rates and post-thaw embryo development (Life Sciences, 2025). Independent work has begun to corroborate the telomerase-activation finding, including a 2025 paper showing epitalon increases telomere length in human cell lines through both telomerase upregulation and alternative lengthening of telomeres (ALT) pathways.

Melatonin Synthesis and Circadian Regulation

Epitalon appears to stimulate melatonin production through the pineal gland. Khavinson’s group showed in female rhesus macaques (Macaca mulatta) of different ages that epitalon significantly stimulated evening melatonin synthesis in senescent monkeys and normalised the circadian rhythm of cortisol secretion (Neuroendocrinology Letters, 2001). This melatonin-restoration pathway is the primary basis for the FDA reviewing epitalon specifically for insomnia rather than the broader anti-aging claims made in the consumer market. The insomnia indication is narrower, but it is also the one with the most plausible mechanistic link to a defined clinical endpoint.

Antioxidant and Gene-Regulatory Effects

A 2025 review in the International Journal of Molecular Sciences (Khavinson et al.) describes additional proposed mechanisms including antioxidant, neuroprotective, and antimutagenic effects. The review notes that epitalon directly influences mRNA levels of interleukin-2, modulates the mitogenic activity of murine thymocytes, and enhances the activity of enzymes including acetylcholinesterase and butyrylcholinesterase. A separate line of in vitro work demonstrated that epitalon enhanced delayed wound healing in a diabetic retinopathy model (Gatta et al., reporting antioxidant activity via the AEDG sequence). These are preclinical findings and should not be conflated with demonstrated clinical efficacy in humans.

The bottom line: Epitalon’s primary proposed mechanism is telomerase reactivation in somatic cells, with secondary effects on pineal melatonin synthesis – the latter being the basis for the FDA’s upcoming insomnia review.

Epitalon has an unusually large body of preclinical research for a peptide that has never entered Western regulatory evaluation. Here is what each tier of evidence actually shows.

In Vitro (Cell Culture) Evidence

The Khavinson 2003 fibroblast study remains the foundational evidence for telomerase activation. It demonstrated hTERT induction, restored TRAP-detectable telomerase activity, and telomere elongation in telomerase-negative cells. The 2019 lymphocyte study (Pendina et al.) extended this to primary human blood cells. The critical caveat is that activating telomerase in a culture dish does not confirm that subcutaneous epitalon injections produce measurable telomere lengthening in living humans – the pharmacokinetic bridge has never been established.

Animal Lifespan Studies

Three species have been tested. In Drosophila melanogaster, Khavinson and colleagues (Mechanisms of Ageing and Development, 2000) showed epitalon increased mean lifespan by 11-16% across two strains, at extremely low concentrations (0.001 x 10^-6 wt.%) that were 1,000-5,000 times lower than epithalamin, suggesting a receptor-mediated rather than dose-dependent effect. The most rigorous mammalian study (Anisimov, Khavinson et al., Biogerontology, 2003) tested 108 female outbred Swiss-derived SHR mice, receiving 1.0 ug/mouse subcutaneously on five consecutive days per month from age 3 months until natural death. Epitalon did not extend the mean lifespan of the population. It did extend the maximum lifespan of the longest-lived animals by approximately 12-13%, reduced chromosomal aberrations by 17.1%, dramatically lowered leukemia rates, and slowed reproductive aging. In HER-2/neu transgenic mice (a breast cancer model), epitalon reduced mammary tumour burden with a 3.7-fold reduction in oncogene mRNA expression (Anisimov et al., International Journal of Cancer, 2002).

Non-Human Primate Evidence

A small study in female rhesus macaques (Khavinson et al., Neuroendocrinology Letters, 2001) demonstrated that epitalon restored evening melatonin secretion in senescent monkeys and normalised cortisol circadian rhythms. This is the strongest preclinical bridge to the insomnia indication under FDA review, as it shows pineal-axis effects in a primate species.

Retinal Protection (The Under-Reported Line)

One of the least-discussed threads in the epitalon literature is the retinal protection work. Khavinson and Razumovsky published three separate studies in Campbell rats, an inbred strain with hereditary pigmentary retinal degeneration (a model for retinitis pigmentosa in humans). In the earliest study (Neuroendocrinology Letters, 2002), epitalon intensified the bioelectric and functional activity of the retina by preserving its morphological structure. The 2002 study in Bulletin of Experimental Biology and Medicine showed that epitalon administration from birth protected the retinal structure, increased bioelectrical activity, and improved function in rats with hereditary retinal dystrophy.

The most striking finding came from a follow-up (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003): when epitalon was administered not only to the offspring during postnatal development but also to the mothers before mating and during pregnancy, retinal morphology and functional activity were preserved for twice as long as untreated controls and 30% longer than animals receiving the peptide only after birth. This transgenerational protective effect has not been reported for any other peptide in the longevity space, though the mechanism remains unexplained. A more recent in vitro study (Gatta et al., non-Khavinson group) demonstrated that epitalon restored impaired wound healing in hyperglycemia-injured retinal pigment epithelial cells (ARPE-19) by inhibiting epithelial-mesenchymal transition and fibrosis – connecting the retinal work to a diabetic retinopathy context and providing the first independent corroboration of retinal-relevant activity.

Anti-Cancer Evidence in Detail

The cancer evidence extends well beyond the transgenic breast cancer model. In a chemically induced colon cancer study (Anisimov et al., Cancer Letters, 2002), 80 outbred male LIO rats were exposed to the carcinogen 1,2-dimethylhydrazine (DMH) and randomised to four treatment groups. Rats receiving epitalon throughout the experiment showed significantly decreased tumour incidence and multiplicity in the ascending and descending colon. Epitalon also inhibited tumour development in the jejunum and ileum (small intestine), extending the protective effect beyond the colon. A follow-up by Kossoy, Zandbank, and colleagues (International Journal of Molecular Medicine, 2003, based at the Laboratory of Experimental Medicine in Rehovot, Israel – not Khavinson’s St. Petersburg group) identified the mechanism: epitalon significantly inhibited mitotic activity of tumour cells while increasing apoptosis (programmed cell death), and it increased lymphoid infiltration in the colon mucosa adjacent to tumours – effectively boosting immune surveillance around pre-malignant tissue. In separate work, epitalon decreased spontaneous tumour incidence (mainly lung adenomas) in female CBA mice and inhibited the growth of transplanted sarcoma M-1. The proposed explanation is epitalon’s documented antioxidant activity: it inhibits free radical processes, which may prevent the oxidative DNA damage that initiates carcinogenesis.

Human Data

The human evidence is the weakest link. Small Russian observational studies using epithalamin (the crude extract, not the synthetic tetrapeptide) reported a 1.6-1.8-fold reduction in mortality in elderly patients over 6 years, and a 15-year observation combining pineal and thymus peptides showed a 2.5-fold reduction in mortality (Khavinson and Morozov, 2003). These studies were not randomised controlled trials, used the natural extract rather than synthetic epitalon, and have not been independently replicated. No properly powered, double-blind, placebo-controlled clinical trial of synthetic epitalon has been published in the peer-reviewed literature to date.

Study	Evidence Tier	Key Finding
Khavinson et al. 2003 (fibroblasts)	In vitro	Induced hTERT, restored telomerase activity, elongated telomeres in human cells
Pendina et al. 2019 (lymphocytes)	In vitro (primary human cells)	Increased telomere length and mitotic index in blood lymphocytes
Khavinson et al. 2000 (Drosophila)	Animal (invertebrate)	11-16% mean lifespan increase at extremely low concentrations
Anisimov et al. 2003 (SHR mice)	Animal (mammalian, n=108)	12-13% maximum lifespan extension, reduced leukemia and chromosomal damage
Anisimov et al. 2002 (HER-2/neu mice)	Animal (cancer model)	3.7-fold reduction in oncogene mRNA expression, reduced tumour burden
Khavinson et al. 2001 (rhesus macaques)	Animal (primate)	Restored evening melatonin synthesis, normalised cortisol rhythm in aged monkeys
Khavinson et al. 2002-2003 (Campbell rats)	Animal (retinal disease model)	Preserved retinal structure and function 2x longer than controls; transgenerational effect when given to mothers
Anisimov 2002 / Kossoy 2003 (colon cancer rats)	Animal (chemically induced cancer, n=80)	Inhibited colon tumour incidence and multiplicity; increased tumour cell apoptosis and immune infiltration
Gatta et al. (ARPE-19 cells, non-Khavinson)	In vitro (diabetic retinopathy model)	Restored wound healing in hyperglycemia-injured retinal cells by inhibiting EMT and fibrosis
Khavinson & Morozov 2003 (elderly patients)	Human (observational, epithalamin extract)	1.6-1.8x mortality reduction over 6 years (uncontrolled, not synthetic epitalon)

The bottom line: The animal data is genuinely interesting – lifespan extension across two species, tumour suppression rather than promotion, and primate melatonin restoration – but the absence of any properly controlled human trial of synthetic epitalon remains the defining gap in the evidence base.

Epitalon has no approved therapeutic product in any country. Its regulatory trajectory is defined almost entirely by the US compounding framework, where it is now approaching the first formal evaluation in Western regulatory history.

Jurisdiction	Status	Detail
United States (FDA)	Removed from Category 2	Removed from Cat 2 on April 15, 2026 (nomination withdrawal). PCAC review scheduled July 24, 2026 for insomnia indication. Not yet eligible for legal compounding.
United Kingdom (MHRA)	Not authorised	No marketing authorisation. Cannot be legally sold for human use. Available from research-chemical suppliers only.
Australia (TGA)	Not approved	No ARTG listing. Personal importation scheme does not guarantee clearance for unapproved peptides.
Russia	Research and clinical use	Used in clinical settings for over 30 years. Formal Russian regulatory pathway details are not transparently documented in Western sources.
WADA	Not specifically listed	Not individually named on the 2024 Prohibited List. May fall under broader peptide hormone categories depending on interpretation. Athletes should treat with extreme caution.

The wider legal position in each market is set out in our guides to peptide legality in the US, UK and Australia.

The bottom line: The upcoming PCAC hearing represents the first time any Western regulator has formally evaluated epitalon for a human therapeutic indication – specifically insomnia, not the broader anti-aging claims.

No systematic safety evaluation of synthetic epitalon has been published in a peer-reviewed clinical trial. The following represents the available safety-relevant information across the entire published record.

In the SHR mouse study (Anisimov et al., 2003), no adverse effects were noted over months of continuous treatment at 1.0 ug/mouse per injection. Food intake and body weight were unaffected. In the transgenic breast cancer model, epitalon did not promote tumour growth and appeared to suppress it, which is notable given the theoretical concern that telomerase activators could fuel malignancies. However, rodent safety data cannot substitute for human pharmacovigilance.

Anecdotal reports from the biohacking community describe epitalon as generally well-tolerated. Commonly reported effects include perceived improvements in sleep quality and energy, with occasional injection-site redness or discomfort. These are uncontrolled observations, not evidence of safety.

The primary theoretical safety concerns are the telomerase-cancer paradox (addressed above – animal data suggests suppression rather than promotion, but unresolved in humans), the lack of any pharmacokinetic data in humans (half-life, bioavailability, and tissue distribution of subcutaneous epitalon are unknown in published literature), and the quality-control risks inherent in a compound available only from unregulated sources with no USP monograph or FDA-approved formulation.

The bottom line: The animal safety profile is reassuring, but the complete absence of controlled human safety data means the risk profile of exogenous epitalon in humans is genuinely unknown.

Any honest assessment of epitalon must address the most significant limitation in its evidence base: the concentration of nearly all published research within a single institution. The St. Petersburg Institute of Bioregulation and Gerontology, under Khavinson’s directorship, has produced the overwhelming majority of the 100-plus papers on epitalon. This is not inherently disqualifying – important compounds have to start somewhere – but it does mean the body of evidence lacks the independent replication that Western pharmaceutical development demands.

Independent corroboration has begun to appear. The 2025 bovine oocyte study (Ullah et al.) came from a non-Khavinson group. A separate 2025 paper demonstrated ALT-pathway telomere lengthening independently. The PCAC review itself will force a formal evidence assessment under Western standards, which will be the most rigorous evaluation epitalon’s research has ever received. But as of mid-2026, the gap between the volume of preclinical evidence and the absence of independent Phase II/III human data remains the central issue.

The bottom line: Epitalon has an unusually deep preclinical research base for a peptide with no approved product, but the evidence is concentrated in one research group, and no randomised controlled trial in humans has been published.

Epitalon sits within the broader longevity peptide landscape. It is one of several Khavinson bioregulators – short peptides developed from tissue-specific extracts – alongside pinealon (another pineal-derived tripeptide) and thymalin (thymic peptide). For a cross-class overview of how telomere peptides, mitochondrial peptides, senolytics, and bioregulators compare, see the Longevity Peptides hub.

The mitochondrial-derived peptide MOTS-c operates through an entirely different mechanism (AMPK activation, metabolic homeostasis) and targets different aging hallmarks (mitochondrial dysfunction, metabolic decline) compared to epitalon’s telomerase and melatonin pathways. The mitochondrial-targeted peptide SS-31 (elamipretide) is the most clinically advanced longevity peptide, with Phase III trial data. The senolytic peptide FOXO4-DRI targets a different aging hallmark altogether (cellular senescence). For the full comparison, the Epitalon vs Pinealon page covers the within-bioregulator head-to-head.

What is the difference between epitalon and epithalamin?

Epithalamin is a crude polypeptide fraction extracted from bovine pineal glands, containing multiple peptides and other molecules. Epitalon is the synthetic four-amino-acid sequence (Ala-Glu-Asp-Gly) identified by Khavinson as the putative active component. The older Russian human studies used epithalamin, not synthetic epitalon – a distinction that matters when evaluating the evidence base.

Does epitalon cause cancer?

The available animal evidence suggests the opposite. In the transgenic breast cancer mouse model, epitalon reduced tumour burden and suppressed oncogene expression. In SHR mice, it lowered leukemia rates. The theoretical concern that telomerase activation could fuel cancer is not supported by any published data on epitalon specifically, though this question has never been rigorously tested in humans.

Why is the FDA reviewing epitalon for insomnia and not anti-aging?

The FDA evaluates substances for specific clinical indications, not broad categories. Insomnia has a defined clinical endpoint (sleep onset latency, total sleep time, sleep quality) that can be measured in a trial. Anti-aging does not have an FDA-accepted clinical endpoint. The melatonin-restoration mechanism demonstrated in primate studies provides the most plausible bridge to a specific, measurable therapeutic claim.

Is epitalon different from melatonin?

Yes – fundamentally. Melatonin is the hormone itself. Epitalon is proposed to stimulate the pineal gland’s production of melatonin endogenously, potentially restoring the natural circadian rhythm rather than supplementing with exogenous hormone. The primate data (Khavinson 2001) showed restored evening melatonin peaks, which is mechanistically distinct from taking a melatonin supplement.

Is epitalon banned by WADA?

Epitalon is not individually named on the 2024 WADA Prohibited List. However, it may fall under the broader categories of prohibited peptide hormones or growth factors depending on regulatory interpretation. Athletes should treat it as a high-risk substance and consult their anti-doping authority before any consideration.

What happens at the PCAC meeting on July 24, 2026?

The Pharmacy Compounding Advisory Committee will evaluate epitalon for potential inclusion on the Section 503A Bulk Drug Substances List for the insomnia indication. The committee considers four factors: physical and chemical characterisation, safety issues, evidence of effectiveness, and historical use in compounding. PCAC recommendations are non-binding but carry significant weight with the FDA. Public comments submitted by July 9, 2026 to Docket No. FDA-2025-N-6895 will be provided to the committee. For the broader timeline and how other peptides are affected, see the RFK Peptide Reclassification Tracker.

Can I buy epitalon legally?

In most Western countries, epitalon can be purchased from research-chemical suppliers labelled “for research use only.” It cannot legally be sold for human consumption in the US, UK, or Australia because it has no marketing authorisation. Compounding is not currently legal in the US because epitalon is not on the 503A Bulks List. This status may change depending on the outcome of the July 2026 PCAC review.